Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics

OBJECTIVE: To describe the clinical characteristics of Latin American patients with metastatic renal cell carcinoma (mRCC) who experienced a progression-free survival (PFS) for at least 15 months following treatment with sunitinib. PATIENTS AND METHODS: In this retrospective analysis, mRCC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Smaletz, Oren, Chacón, Matias, de Oliveira Koch, Ludmila, de Carvalho Rocha, Daniela R, Cardoso, Fernanda C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138036/
https://www.ncbi.nlm.nih.gov/pubmed/27942224
http://dx.doi.org/10.2147/OTT.S111137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138036/
https://www.ncbi.nlm.nih.gov/pubmed/27942224
http://dx.doi.org/10.2147/OTT.S111137

Ejemplares similares